Literature DB >> 22322541

"Atypical femoral fractures" during bisphosphonate exposure in adult hypophosphatasia.

Roger A L Sutton1, Steven Mumm, Stephen P Coburn, Karen L Ericson, Michael P Whyte.   

Abstract

We report a 55-year-old woman who suffered atypical subtrochanteric femoral fractures (ASFFs) after 4 years of exposure to alendronate and then zolendronate given for "osteoporosis." Before alendronate treatment, she had low bone mineral density. After several months of therapy, metatarsal stress fractures began. Bisphosphonate (BP) administration was stopped following the ASFFs, and the adult form of hypophosphatasia (HPP) was diagnosed from low serum alkaline phosphatase (ALP) activity, high endogenous levels of two natural substrates for the "tissue-nonspecific" isoenzyme of ALP (TNSALP), and a heterozygous mutation within the gene that encodes this enzyme. Experience with other HPP families showed that her mutation (Arg71His) with a second defective TNSALP allele can cause severe HPP in infancy, and when heterozygous can cause mild HPP featuring premature loss of deciduous teeth in children. Because the skeletal disease of HPP results from extracellular accumulation of the TNSALP substrate inorganic pyrophosphate (PPi) and its inhibitory effect on mineralization, perhaps HPP patients or carriers will have adverse effects from BPs. BPs are analogues of PPi and can suppress bone turnover but also deactivate TNSALP. Our report is the first of BP exposure preceding ASFFs in adult HPP. To explore a potential role for TNSALP deactivation in ASFFs, mutation analysis of TNSALP should be studied in a cohort of these patients. Meanwhile, clinicians must suspect HPP when clinical or laboratory clues include premature loss of primary dentition, pseudofractures or recurrent poorly healing metatarsal stress fractures, a family history suggestive of HPP, or low serum ALP activity. If HPP is documented, BP treatment might be avoided. To establish the diagnosis of HPP, assays for two natural substrates for TNSALP and TNSALP mutation analysis are available in commercial laboratories. With positive findings, radiological or bone biopsy evidence of acquired osteomalacia would indicate the adult form of this inborn-error-of-metabolism.
Copyright © 2012 American Society for Bone and Mineral Research.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22322541     DOI: 10.1002/jbmr.1565

Source DB:  PubMed          Journal:  J Bone Miner Res        ISSN: 0884-0431            Impact factor:   6.741


  60 in total

Review 1.  Clinical management of hypophosphatasia.

Authors:  Nick Bishop
Journal:  Clin Cases Miner Bone Metab       Date:  2015-10-26

2.  Mutational and biochemical findings in adults with persistent hypophosphatasemia.

Authors:  F E McKiernan; J Dong; R L Berg; E Scotty; P Mundt; L Larson; I Rai
Journal:  Osteoporos Int       Date:  2017-04-12       Impact factor: 4.507

3.  Clinical utility gene card for: hypophosphatasia - update 2013.

Authors:  Etienne Mornet; Christine Hofmann; Agnès Bloch-Zupan; Hermann Girschick; Martine Le Merrer
Journal:  Eur J Hum Genet       Date:  2013-08-07       Impact factor: 4.246

4.  Acute severe hypercalcemia after traumatic fractures and immobilization in hypophosphatasia complicated by chronic renal failure.

Authors:  Michael P Whyte; Rattana Leelawattana; William R Reinus; Chang Yang; Steven Mumm; Deborah V Novack
Journal:  J Clin Endocrinol Metab       Date:  2013-09-24       Impact factor: 5.958

5.  Low-energy trauma-induced intercondylar femoral fracture.

Authors:  Mathias Aeby; Tobias Wyss; Birgit Mentrup; Erdmute Kunstmann; Franz Jakob; Daniel Aeberli
Journal:  Clin Cases Miner Bone Metab       Date:  2016-10-05

Review 6.  [Pathological and metabolic bone diseases: Clinical importance for fracture treatment].

Authors:  R Oheim
Journal:  Unfallchirurg       Date:  2015-12       Impact factor: 1.000

7.  Hypophosphatasia - pathophysiology and treatment.

Authors:  José Luis Millán; Horacio Plotkin
Journal:  Actual osteol       Date:  2012-09-01

8.  Abnormal bone turnover in individuals with low serum alkaline phosphatase.

Authors:  L López-Delgado; L Riancho-Zarrabeitia; M T García-Unzueta; J A Tenorio; M García-Hoyos; P Lapunzina; C Valero; J A Riancho
Journal:  Osteoporos Int       Date:  2018-06-12       Impact factor: 4.507

Review 9.  [Hypophosphatasia : What is currently available for treatment?]

Authors:  T Schmidt; M Amling; F Barvencik
Journal:  Internist (Berl)       Date:  2016-12       Impact factor: 0.743

10.  Efficacy of anti-sclerostin monoclonal antibody BPS804 in adult patients with hypophosphatasia.

Authors:  Lothar Seefried; Jasmin Baumann; Sarah Hemsley; Christine Hofmann; Erdmute Kunstmann; Beate Kiese; Yue Huang; Simon Chivers; Marie-Anne Valentin; Babul Borah; Ronenn Roubenoff; Uwe Junker; Franz Jakob
Journal:  J Clin Invest       Date:  2017-04-24       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.